Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
about
Yellow fever vaccines and international travelersA Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine CandidatesMulti-walled carbon nanotubes increase antibody-producing B cells in mice immunized with a tetravalent vaccine candidate for dengue virusGuiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccineEndothelial cells in dengue hemorrhagic feverThe yellow fever 17D virus as a platform for new live attenuated vaccinesMouse models to study dengue virus immunology and pathogenesisDengue viruses - an overviewRecombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines.Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys.Yellow fever virus replicons as an expression system for hepatitis C virus structural proteinsA Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in MonkeysYellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse ModelAn adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypesAn Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling MiceProduction of Pseudoinfectious Yellow Fever Virus with a Two-Component GenomeHigh Genetic Stability of Dengue Virus Propagated in MRC-5 Cells as Compared to the Virus Propagated in Vero CellsDengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine DevelopmentReplication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2Live Chimeric and Inactivated Japanese Encephalitis Virus Vaccines Differ in Their Cross-Protective Values against Murray Valley Encephalitis VirusEvaluation of Chimeric Japanese Encephalitis and Dengue Viruses for Use in Diagnostic Plaque Reduction Neutralization TestsVaccines: the Fourth CenturyEmerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue virusesIssues related to recent dengue vaccine development.Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.RNA virus reverse genetics and vaccine design.Dengue type 4 live-attenuated vaccine viruses passaged in vero cells affect genetic stability and dengue-induced hemorrhaging in miceDengue vaccines: state of the art.Utility, limitations, and future of non-human primates for dengue research and vaccine developmentEvaluation of three commercially available Japanese encephalitis virus IgM enzyme-linked immunosorbent assays.Dengue vaccines: recent developments, ongoing challenges and current candidates.Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunityThe synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.CD8+ T lymphocyte expansion, proliferation and activation in dengue fever.Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.Recent advancement in flavivirus vaccine development.Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic.Prospective cohort study with active surveillance for fever in four dengue endemic countries in Latin AmericaDengue vaccine: priorities and progress.
P2860
Q22305943-AF7B146E-FBB4-419E-BFF1-2B9B845A627CQ24282617-1EC803F4-C779-4218-8CB2-843005BCAFFFQ26700122-B773B1E3-2473-4E31-A4F3-CFC5B75AFF6DQ26782367-F3D084E5-9BFF-4A01-9BE9-90EB90FA5EC5Q26825663-66AB58DC-F051-47EA-A514-BD2217E41631Q26865102-5344936A-D915-4419-A1C4-12977DF5796AQ27010151-7E2B0940-CB60-4E34-878A-326337D3227CQ27026302-48BBEB46-2D7C-4EFE-8B16-AAEB25DCC43FQ27469474-BC772989-2217-4D6A-B67C-8D3ECA6C1634Q27472841-5C82D884-FB55-4498-8AF2-7361DDF897ABQ27472847-F389572E-6E42-4008-B59E-1F02D7E3294FQ27473075-E08F1899-E8ED-43E4-B497-670411ECFFF1Q27473080-827A5ED3-D401-4E94-B7DB-26B80C96D2B4Q27473317-6E56AEA8-F4B9-4F49-9FBE-B057054ACEDCQ27478104-12692353-CD07-4D81-8DD1-8E25FD6C452BQ27481478-8F2E7AF6-9E15-403F-80FF-E6C3943EA603Q27484992-EB4E2F18-A0E2-4407-AC6D-4E46D0EA4399Q27485473-4BF46BC8-679A-44C0-9D47-DDC46ADBE4ADQ27485759-A316FF91-0C9C-4303-A06A-905878396B85Q27487570-C7EEE2E3-3F1E-4206-A387-F10184623D6EQ27487967-2B5857D3-A0DE-4798-ADF8-F8D081E08783Q27488878-0F9309AC-CF53-4797-B2E4-28A50881D1A3Q27490454-35EAF01A-116A-4498-8757-9A9A2B1DA7A2Q27860800-E379ACC3-72F8-453C-9180-DF95906FAF65Q30395396-AA98D9D9-14CB-4D61-8B39-81DA6734CFC9Q33723518-75484DB7-99A7-4D8E-A174-29DFB167E9FBQ33963398-56FDA9F6-32B9-405E-91BF-83502CB47BFEQ34066921-878BFA24-E217-4893-9E7B-9F15402BBBA5Q34109652-10AB7E4D-6055-4CE4-8D8B-626D0E79B8BEQ34238916-0C2EF51C-6534-4FB3-BFE4-74F40E85B5AFQ34240178-F8B78DDB-BEA5-4F6C-B257-E61B23114C44Q34367194-635C06FF-2937-4562-AFFC-BEC31A37E7B8Q34491896-C9F07499-C7AD-4585-A181-D659E6F77ACBQ34614953-1FE1F083-37CE-401C-94E3-0F7CCAB1B00DQ35078921-557BDE40-2A9E-4BB9-973C-2F3CC01FC82CQ35246126-BF11D19A-D456-4EF6-A8DE-96F0A8AA41F3Q35728621-3ABD7B03-00BD-4BA8-BFC4-EC3EBFCBB0FDQ35802862-EFB28527-4049-47AF-A30B-A6418E47FC71Q35836631-B8A0ED77-5A91-4DD6-B783-E1F2310309A0Q35964754-1A3A9B57-EE58-4E7D-807C-FBABA9777F1D
P2860
Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Construction, Safety, and Immu ...... ngue Virus Tetravalent Vaccine
@nl
Construction, safety, and immu ...... gue virus tetravalent vaccine.
@ast
Construction, safety, and immu ...... gue virus tetravalent vaccine.
@en
type
label
Construction, Safety, and Immu ...... ngue Virus Tetravalent Vaccine
@nl
Construction, safety, and immu ...... gue virus tetravalent vaccine.
@ast
Construction, safety, and immu ...... gue virus tetravalent vaccine.
@en
prefLabel
Construction, Safety, and Immu ...... ngue Virus Tetravalent Vaccine
@nl
Construction, safety, and immu ...... gue virus tetravalent vaccine.
@ast
Construction, safety, and immu ...... gue virus tetravalent vaccine.
@en
P2093
P2860
P3181
P1433
P1476
Construction, safety, and immu ...... gue virus tetravalent vaccine.
@en
P2093
K Georgakopoulos
K V Pugachev
M Ratterree
P2860
P304
P3181
P356
10.1128/JVI.75.16.7290-7304.2001
P577
2001-08-01T00:00:00Z